WO1999003508A3 - METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF - Google Patents

METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF Download PDF

Info

Publication number
WO1999003508A3
WO1999003508A3 PCT/US1998/015025 US9815025W WO9903508A3 WO 1999003508 A3 WO1999003508 A3 WO 1999003508A3 US 9815025 W US9815025 W US 9815025W WO 9903508 A3 WO9903508 A3 WO 9903508A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusions
proliferative diseases
vascular proliferative
treating vascular
treating
Prior art date
Application number
PCT/US1998/015025
Other languages
French (fr)
Other versions
WO1999003508A9 (en
WO1999003508A2 (en
Inventor
Gary J Nabel
Elizabeth G Nabel
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Priority to DE69836139T priority Critical patent/DE69836139T2/en
Priority to CA002295199A priority patent/CA2295199C/en
Priority to AU85021/98A priority patent/AU8502198A/en
Priority to JP2000502802A priority patent/JP2001510028A/en
Priority to EP98935852A priority patent/EP0998307B1/en
Publication of WO1999003508A2 publication Critical patent/WO1999003508A2/en
Publication of WO1999003508A3 publication Critical patent/WO1999003508A3/en
Publication of WO1999003508A9 publication Critical patent/WO1999003508A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention is directed to a method of vascular proliferative disease by administering in vivo a gene encoding p27.
PCT/US1998/015025 1997-07-21 1998-07-21 METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF WO1999003508A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69836139T DE69836139T2 (en) 1997-07-21 1998-07-21 METHOD FOR THE TREATMENT OF VASCULAR PROLIFERATIVE DISEASES WITH P27 AND FUSIONS THEREOF
CA002295199A CA2295199C (en) 1997-07-21 1998-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof
AU85021/98A AU8502198A (en) 1997-07-21 1998-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof
JP2000502802A JP2001510028A (en) 1997-07-21 1998-07-21 Methods for treating vascular proliferative disorders with p27 and fusions thereof
EP98935852A EP0998307B1 (en) 1997-07-21 1998-07-21 METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/897,333 US6177272B1 (en) 1997-07-21 1997-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof
US08/897,333 1997-07-21

Publications (3)

Publication Number Publication Date
WO1999003508A2 WO1999003508A2 (en) 1999-01-28
WO1999003508A3 true WO1999003508A3 (en) 1999-04-08
WO1999003508A9 WO1999003508A9 (en) 1999-05-14

Family

ID=25407780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/015025 WO1999003508A2 (en) 1997-07-21 1998-07-21 METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF

Country Status (8)

Country Link
US (2) US6177272B1 (en)
EP (1) EP0998307B1 (en)
JP (1) JP2001510028A (en)
AT (1) ATE342067T1 (en)
AU (1) AU8502198A (en)
CA (1) CA2295199C (en)
DE (1) DE69836139T2 (en)
WO (1) WO1999003508A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413943B1 (en) 1999-03-01 2002-07-02 Cell Genesys, Inc. Methods and reagents for inhibiting proliferation of smooth muscle cells
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US6521602B1 (en) 1999-03-01 2003-02-18 Gpc Biotech Inc. Anti-neoplastic compositions and uses thereof
JP4684512B2 (en) 1999-09-22 2011-05-18 信之 宮坂 p21Cip1 Rheumatoid Treatment
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
JP5100951B2 (en) * 2000-09-29 2012-12-19 コーディス・コーポレイション Coated medical device
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020098998A1 (en) * 2001-01-22 2002-07-25 Marks Andrew R. P27 prevents cellular migration
US20030013638A1 (en) * 2001-01-22 2003-01-16 Marks Andrew R. P27 prevents cellular migration
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US20030065345A1 (en) * 2001-09-28 2003-04-03 Kevin Weadock Anastomosis devices and methods for treating anastomotic sites
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
WO2006031210A1 (en) 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
CA2715765A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
CN114401992A (en) 2019-07-05 2022-04-26 艾欧麦克斯治疗股份公司 Antibodies to IGSF11(VSIG3) that bind IGC2 and uses thereof
US20240010720A1 (en) 2020-07-06 2024-01-11 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018824A1 (en) * 1994-01-07 1995-07-13 Sloan-Kettering Institute For Cancer Research ISOLATED p27 PROTEIN AND ITS ENCODING NUCLEIC ACID MOLECULES

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6355774B1 (en) 1994-01-07 2002-03-12 Fred Hutchinson Cancer Research Center Isolated p27 protein
US6242575B1 (en) 1994-01-07 2001-06-05 Fred Hutchinson Institute For Cancer Research Antibodies for detecting p27 protein
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
AU2770695A (en) 1994-07-15 1996-02-16 Fred Hutchinson Cancer Research Center Isolated p27 protein and methods for its production and use
WO1996025507A2 (en) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6541197B2 (en) * 1996-01-22 2003-04-01 Human Gene Therapy Research Institute Vehicles for stable transfer of green fluorescent protein gene and methods of use for same
US5672508A (en) * 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
WO1998021350A1 (en) * 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018824A1 (en) * 1994-01-07 1995-07-13 Sloan-Kettering Institute For Cancer Research ISOLATED p27 PROTEIN AND ITS ENCODING NUCLEIC ACID MOLECULES

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRAUN-DULLAEUS, R. C. ET AL: "Regulation of vascular smooth muscle cell proliferation by the cyclin-dependent kinase inhibitor P27 - KIP1.", JOURNAL OF INVESTIGATIVE MEDICINE, (1997) VOL. 45, NO. 3, PP. 224A. MEETING INFO.: ANNUAL MEETING OF THE ASSOCIATION OF AMERICAN PHYSICIANS, THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, AND THE AMERICAN FEDERATION FOR MEDICAL RESEARCH: BIOMEDICIN, XP002087801 *
CHEN D ET AL: "Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27 ( KIP1 ), an inhibitor of neointima formation in the rat carotid artery.", JOURNAL OF CLINICAL INVESTIGATION, (1997 MAY 15) 99 (10) 2334-41. JOURNAL CODE: HS7. ISSN: 0021-9738., United States, XP002087800 *
TANNER F C ET AL: "Expression of cyclin-dependent kinase inhibitors in vascular disease.", CIRCULATION RESEARCH, (1998 FEB 23) 82 (3) 396-403. JOURNAL CODE: DAJ. ISSN: 0009-7330., United States, XP002087803 *
TANNER, FELIX C. ET AL: "Gene transfer of p27KIP2 and p21CIP1 cyclin-dependent kinase inhibitors, but not p16INK negatively regulate VSMC proliferation through differential effects on kinase activity.", CIRCULATION, (10/21/97, 1997) VOL. 96, NO. 8 SUPPL., PP. I5. MEETING INFO.: 70TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION ORLANDO, FLORIDA, USA NOVEMBER 9-12, 1997 ISSN: 0009-7322., XP002087804 *
TOYOSHIMA ET AL: "P27, A NOVEL INHIBITOR OF G1 CYLIN-CDK PROTEIN KINASE ACTIVITY, IS RELATED TO P21", CELL, vol. 78, 1994, pages 67 - 74, XP002087802 *

Also Published As

Publication number Publication date
CA2295199C (en) 2007-07-03
DE69836139T2 (en) 2007-08-16
WO1999003508A9 (en) 1999-05-14
US6177272B1 (en) 2001-01-23
EP0998307B1 (en) 2006-10-11
US6884431B1 (en) 2005-04-26
DE69836139D1 (en) 2006-11-23
EP0998307A2 (en) 2000-05-10
AU8502198A (en) 1999-02-10
ATE342067T1 (en) 2006-11-15
WO1999003508A2 (en) 1999-01-28
CA2295199A1 (en) 1999-01-28
JP2001510028A (en) 2001-07-31

Similar Documents

Publication Publication Date Title
WO1999003508A3 (en) METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF
SE8902638L (en) STABILIZED PROTEIN OR PEPTIDE CONJUGATE
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ZA943464B (en) Vascular endothelial growth factor 2
AU1805499A (en) Method and apparatus for delivery of therapeutic agents to the heart
WO2001036640A3 (en) Human fgf-21 gene and gene expression products
AU9028798A (en) Method of improving drug treatment
AU4528493A (en) In vivo gene therapy with intron-free sequence of interest
NZ269653A (en) Treatment of protein kinase c-related diseases by gene therapy
ZA943465B (en) Transforming growth factor alpha H1
NO904378L (en) PROCEDURE FOR THE PREPARATION OF A MODIFIED PROTEIN FOR THERAPEUTIC USE.
HUP9800467A3 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
EP1136561A3 (en) Targeting gene therapy
WO2000040273A8 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
AU6459596A (en) Methods of treatment of neurological diseases by interferon antagonists
WO1997009420A3 (en) Dna sequences coding for a human metalloproteinase and variants thereof
DE69007065D1 (en) Use of diadenosine 5 ', 5' '' - p1, p4-tetraphosphate for the manufacture of a medicament for the treatment of heart diseases.
AU9494998A (en) (in vivo), animal model for expression of hepatitis c virus
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
AU2390797A (en) Sequences ahead of gene sm22, vectors containing same, and therapeutical uses thereof, particularly for treating vascular diseases
AU6406098A (en) Use of minalcipran and its derivatives for preparing a medicine for treating certain psychiatric diseases
HUP0004647A3 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
WO1999056767A3 (en) Method for treating cytokine mediated hepatic injury
AU4037299A (en) Genetically-modified fibroblasts and the use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 2/7-6/7, DRAWINGS, REPLACED BY NEW PAGES 2/7-6/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2295199

Country of ref document: CA

Ref country code: CA

Ref document number: 2295199

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998935852

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998935852

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1998935852

Country of ref document: EP